Look back at pharma news in week to Mar 23
The big news stories last week featured clinical research, with some positive results and a disappointment. First up, Regeneron presented strong new data on Eylea that could open up a wider ophthalmic market for it and partner Bayer. Late-stage data on Heron Therapeutics' pain drug HTX-011 suggests it has a faster regulatory path. On the negative side, AbbVie’s lung cancer drug Rova-T (rovalpituzumab tesirine) failed to achieve objectives, while Novo Nordisk added to the promise of semaglutide in the treatment of obesity.
Panorama opens a new vista for Eylea
Regeneron announced that the results for the PANORAMA trial of Eylea in patients with moderate to non-proliferative diabetic retinopathy (NPDR) met the 24-week primary endpoint. “This result came sooner than we anticipated and was more positive than we anticipated, at least from the company’s first press released top-line results,” noted Leerink analyst Geoffrey Porges
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze